Who is the CEO of Cellid?

According to the DART company overview, Cellid's representative director is 강창율 (name as registered in Korean). The company was founded on 2006-12-01.

Where is Cellid listed?

Cellid trades on the Korea Exchange KOSDAQ market under the ticker 299660. Its fiscal year ends in December.

Does Cellid pay a dividend?

Cellid did not pay a cash dividend for fiscal 2025, according to its annual report.

Does Cellid have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); 4 quarters of losses (operating loss in each of the last four quarters); Control change (change of largest shareholder, or a contract that would cause one (90 days)); Private placement (third-party allotment rights offering decided in the past 90 days). 1 more signal is shown on the page. These are factual flags, not investment advice.

Which companies are in the same industry as Cellid?

Under the Korean Standard Industrial Classification recorded on DART, Cellid is grouped with 77 other listed companies in research & development. The most covered in Korean news over the past 30 days are SK biopharmaceuticals, Alteogen and D&D Pharmatech.

Cellid KRX:299660KOSDAQ

셀리드 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days3

DART filings, 7 days1

Articles tracked50since Sep 11

In Q2 2026, Cellid reported revenue of ₩2.1bn, down 3.0% year on year, and an operating loss of ₩2.5bn. Cellid (셀리드) appeared in 3 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 4 with 2 articles. It was most often mentioned alongside GC Cell.

Filing signals Control change Private placement Dilution risk 4 quarters of losses Litigation Screener

Cellid quarterly results separate, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩2.1bn	-3.0%	−₩2.5bn margin −121.2%	−₩19.0bn
Q1 2026	₩3.2bn	+104.4%	−₩1.6bn margin −50.3%	−₩1.5bn
Q4 2025 derived	₩2.8bn	+49.2%	−₩3.7bn margin −131.1%	−₩4.5bn
Q3 2025	₩2.3bn	+70.4%	−₩2.5bn margin −109.2%	−₩2.4bn
Q2 2025	₩2.1bn	+255.3%	−₩2.4bn margin −113.2%	−₩2.5bn
Q1 2025	₩1.6bn	+399.4%	−₩2.7bn margin −172.0%	−₩2.7bn
Q4 2024 derived	₩1.9bn	–	−₩3.6bn margin −191.6%	−₩3.6bn
Q3 2024	₩1.4bn	–	−₩2.7bn margin −198.2%	−₩2.8bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Cellid top stories 2 weeks, by number of outlets

1
Regulatory filing: Cellid major matters report (lawsuit filing)
1 outlets · 1 articlesFirst report Nov 9 19:30 스페셜타임스
2
HIT Alert: Cellid faces lawsuit over 1.1 million share new issuance invalidation
1 outlets · 1 articlesFirst report Nov 9 18:00 히트뉴스
3
Cellid relieves Magok new office PF burden, defers repayment until November next year
1 outlets · 1 articlesFirst report Nov 4 14:05 한스경제
4
Cellid faces lawsuit over third-party placement rights offering regarding share issuance invalidation
1 outlets · 1 articlesFirst report Nov 10 08:03 EBN
5
Cellid refinances Magok project finance 32.56 billion won collateral loan
1 outlets · 1 articlesFirst report Nov 3 14:24 비건뉴스
6
Bio Talk - GC Cell strengthening market dominance with bio logistics specialized infrastructure and others Btigen, Cellid
1 outlets · 1 articlesFirst report Nov 4 14:03 글로벌경제신문GC Cell

Latest Cellid news Korean headlines

Nov 1008:03

Cellid faces lawsuit over third-party placement rights offering regarding share issuance invalidation
EBN
Nov 919:30

Regulatory filing: Cellid major matters report (lawsuit filing)
스페셜타임스
Nov 918:00

HIT Alert: Cellid faces lawsuit over 1.1 million share new issuance invalidation
히트뉴스
Nov 414:05

Cellid relieves Magok new office PF burden, defers repayment until November next year
한스경제
Nov 414:03
Bio Talk - GC Cell strengthening market dominance with bio logistics specialized infrastructure and others Btigen, Cellid
글로벌경제신문GC Cell
1 more on this story · 1 outlets
- GC Cell strengthening competitiveness with bio logistics specialized infrastructure베타뉴스 · Nov 4 15:19
Nov 314:24

Cellid refinances Magok project finance 32.56 billion won collateral loan
비건뉴스
Oct 3017:18

Cellid faces halt on 10 billion won rights offering and management rights transfer...injunction filed
뉴데일리경제
Oct 2819:13

Regulatory filing: Cellid major matters report (lawsuit filing)
스페셜타임스
Oct 2819:13

Cellid regulatory filing: lawsuit filing and application (management rights dispute litigation) (new shares issuance injunction)
스페셜타임스
Oct 714:51

MajorCellid pursues patent acquisition for vaccine antigen technology in China and India, expanding Asia business foundation
파이낸셜뉴스New technology
Oct 713:46
MajorCellid COVID-19 vaccine antigen platform patent registration in China and India decided, Asian rights expanded
이투데이New technology
1 more on this story · 1 outlets
- Cellid COVID-19 vaccine antigen technology patents in China and India, expanded to 7 countries메디컬투데이 · Oct 7 14:28
Oct 713:26

MajorCellid breaks into China and India, COVID-19 vaccine antigen platform technology patent registration success
프라임경제New technology
Oct 713:19
MajorCellid COVID-19 vaccine antigen technology patent registration decided in China and India
PRESS9New technology
4 more on this story · 4 outlets
- Cellid antigen platform technology applied to COVID-19 vaccine patent registration decided in China and India뉴스타운 · Oct 7 13:24
- Cellid antigen platform technology applied to COVID-19 vaccine patent registration in China and India머니투데이 · Oct 7 13:47
- Cellid COVID-19 vaccine antigen platform patent registration decided in China and India뉴스핌 · Oct 7 14:48
- Cellid antigen platform technology applied to COVID-19 vaccine patent registration decided in China and India매일경제 · Oct 7 15:06
Oct 711:51

BIO talk: Lotte Biologics and Albotech collaborate on global biosimilar production, others including GI Innovation and Cellid
글로벌경제신문GI Innovation 글로벌테크놀로지
Oct 614:54

Cellid zoom-up: FI investor behind new major shareholder, Cellid at risk of becoming a 'shell'③
녹색경제신문
Sep 2915:41

Cellid zoom-up: New major shareholder Huniverse Global, will 'additional investment' come with management control acquisition premise②
녹색경제신문Stake / acquisition
Sep 2811:57

Cellid failed phase 3 corona vaccine trial, after raising 130 billion won, ownership changes hands
데일리팜
Sep 2811:04

Huniverse Global with 800 million won capital becomes Cellid's largest shareholder, funding raised through EB
뉴데일리경제
Sep 2408:38

Cellid, Blue M Tech stir with management control sale news; Inventera rises
이데일리Stake / acquisitionInventera Bluemtec
Sep 2312:19

Cellid zoom-up: CEO Kang Chang-yul's decision to relinquish ownership and pursue 'R&D strategy'①
녹색경제신문
Sep 2310:36

Cellid stock rises 7.63% to 3,105 won intra-day on September 23
중앙이코노미뉴스
Sep 2309:48

Huniverse Global invests 10 billion won in Cellid, becomes largest shareholder
한국경제
Sep 2309:42

Cellid conducts 10 billion won third-party placement rights offering, Huniverse Global becomes largest shareholder
히트뉴스
Sep 2308:04

Cellid raises 10 billion won through third-party rights offering, largest shareholder changes
한스경제
Sep 2300:20

Cellid receives 10 billion won infusion, Huniverse Global becomes new owner
월요신문Stake / acquisition
Sep 2218:29

Cellid conducts 3 billion won rights offering with third-party placement to Centrust Investment Consortium and others
연합뉴스경제
Sep 2218:05

Popular searches top 5: Nota, Cellid, LG Electronics, Samsung Electro-Mechanics, SK hynix
매일경제SK hynix Samsung Electro-mechanics LG Electronics Nota
Sep 2218:02

Cellid conducts 10 billion won rights offering
매일경제
Sep 2217:45
Cellid hands over management rights to Huniverse Global with 10 billion won rights offering
이데일리
2 more on this story · 2 outlets
- Cellid hands over management rights to Huniverse Global with 10 billion won rights offering이데일리 · Sep 22 17:44
- Cellid hands over management rights to Huniverse Global with 10 billion won rights offering이데일리증권 · Sep 22 17:44
Sep 2216:52

Huniverse Global invests 10 billion won in Cellid, becoming largest shareholder
더바이오

Articles per day 2 weeks

110

Company profile

CEO: 강창율
Industry: Research & development
Founded: 2006-12-01
Fiscal year-end: December
Head office: 서울특별시 관악구
Website: cellid.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Same industry Research & development

All in industry

Company	Latest quarter op. profit	Articles 30d
SK biopharmaceuticals	–	324
Alteogen	–	255
D&D Pharmatech	−₩13.6bn	72
LigaChem Biosciences	−₩50.4bn	69
Curocell	−₩7.7bn	51
HLB Pharmaceutical	₩847m	44
SillaJen	–	44
Onconic Therapeutics	–	43

Compare Cellid side by side with these companies

Cellid DART filings

Nov 916:11

Material event report (Commencement of litigation, etc.)
Risk & warnings
Nov 618:02

[Corrected filing] Decision on provision of collateral to third parties
Other
Nov 517:28

Judgment or ruling on lawsuits or applications
Risk & warnings
Nov 417:56

Corrected filing: Litigation and proceedings (management rights dispute) (preliminary injunction against new share issuance)
Risk & warnings
Nov 417:56

Corrected filing: Material events report (litigation)
Risk & warnings
Nov 414:13

Corrected filing: Execution of contract regarding change of control
Capital & M&A
Nov 414:10

Material matters report (rights offering approval) (corrected filing)
Capital & M&A
Nov 413:44

Correction: Shareholder meeting convocation resolution (extraordinary general meeting)
Other
Nov 217:40

Short-term borrowing increase decision
Other
Nov 217:03

Decision on provision of collateral to third parties
Other
Oct 2916:22

Corrected filing: Small-scale offering results report
Other
Oct 2915:24

Material matters report (rights offering approval) (corrected filing)
Capital & M&A

Mentioned alongside 2 weeks

1 GC CellKOSDAQ 1

Cellid FAQ

Who is the CEO of Cellid?: According to the DART company overview, Cellid's representative director is 강창율 (name as registered in Korean). The company was founded on 2006-12-01.
Where is Cellid listed?: Cellid trades on the Korea Exchange KOSDAQ market under the ticker 299660. Its fiscal year ends in December.
What were Cellid's latest quarterly results?: In Q2 2026, Cellid reported revenue of ₩2.1bn, down 3.0% year on year, and an operating loss of ₩2.5bn. Figures come from reports filed on DART.
Does Cellid pay a dividend?: Cellid did not pay a cash dividend for fiscal 2025, according to its annual report.
Does Cellid have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); 4 quarters of losses (operating loss in each of the last four quarters); Control change (change of largest shareholder, or a contract that would cause one (90 days)); Private placement (third-party allotment rights offering decided in the past 90 days). 1 more signal is shown on the page. These are factual flags, not investment advice.
Which companies are in the same industry as Cellid?: Under the Korean Standard Industrial Classification recorded on DART, Cellid is grouped with 77 other listed companies in research & development. The most covered in Korean news over the past 30 days are SK biopharmaceuticals, Alteogen and D&D Pharmatech.